AG-MOXIFLOXACIN 0.5 %
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 0.5 % · DIN 02484757 · ANGITA PHARMA INC.
Health Canada status: DORMANT
What is AG-MOXIFLOXACIN?
AG-MOXIFLOXACIN 0.5 % contains MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 02484757, held by ANGITA PHARMA INC., supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as dormant, status dated 30-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AG-MOXIFLOXACIN used for?
Treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of aerobic Gram-positive and Gram-negative organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02484757 |
|---|---|
| Brand name | AG-MOXIFLOXACIN |
| Generic / active ingredient | MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 0.5 % |
| Manufacturer | ANGITA PHARMA INC. |
| Strength | 0.5 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01AE07 MOXIFLOXACIN |
| AHFS class | 52:04.04 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 30-Jul-2025 |
| Original market date | 2020-07-09 00:00:00 |
How is it administered?
One drop in the affected eye(s) 3 times a day for 7 days. Care must be taken not to touch the dropper tip to surfaces to prevent contamination.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15°C-30°C. Discard the product 28 days after opening. Keep out of reach of children.
How is it supplied?
3 mL sterile ophthalmic solution in round LDPE dropper bottle with HDPE Screw Cap.
Contraindications
Hypersensitivity to moxifloxacin, other quinolones, or any ingredient in the formulation or component of the container.
Warnings and precautions
For ocular use only; not for injection. Serious hypersensitivity (anaphylactic) reactions reported with systemic quinolones. Prolonged use may result in overgrowth of non-susceptible organisms.
Is MOXIFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01AE07 MOXIFLOXACIN. 5 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MOXIFLOXACIN | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02406373 |
| MOXIFLOXACIN | 0.5 % | SOLUTION | SANIS HEALTH INC | MARKETED | DIN 02529076 |
| PMS-MOXIFLOXACIN | 0.5 % | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02432218 |
| SANDOZ MOXIFLOXACIN | 0.5 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02411520 |
| VIGAMOX | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02252260 |
| ACT MOXIFLOXACIN | 0.5 % | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02404656 |
| JAMP-MOXIFLOXACIN | 0.5 % | SOLUTION | JAMP PHARMA CORPORATION | DORMANT | DIN 02472120 |
| MOXIFLOXACIN OPHTHALMIC SOLUTION | 0.5 % | SOLUTION | BEXIMCO PHARMACEUTICALS CANADA LIMITED | APPROVED | DIN 02485702 |
| MYLAN-MOXIFLOXACIN HCL OPHTHALMIC SOLUTION | 0.5 % | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02429578 |
| TEVA-MOXIFLOXACIN | 0.5 % | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02420511 |
Who else supplies MOXIFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOXIFLOXACIN appears in 153 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.